

# Mozobil® (plerixafor injection) Billing Instruction Sheet



## Completing the CMS-1500 Claim Form for Physician Offices

Most third-party payers, including Medicare, state Medicaid plans, managed care organizations, indemnity plans, and others, provide coverage for Mozobil when administered in a physician's office.

### CLAIMS SUBMISSION

Physicians submit a CMS-1500 (08-05) claim form or its electronic equivalent for Mozobil. Physicians report various codes on the claim form to indicate the medical necessity for Mozobil and its administration in order to receive proper payment from payers.

### DIAGNOSIS CODE(S)

All payers recognize International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes to indicate the medical necessity for Mozobil. The physician must list an appropriate diagnosis code for Mozobil in Box 21 DIAGNOSIS OR NATURE OF ILLNESS OR INJURY of the CMS-1500 claim form and then link the diagnosis to Box 24E DIAGNOSIS POINTER of the corresponding line. Payers may delay processing, deny, or reject claims without valid diagnoses, requiring the physician to complete and resubmit a corrected claim.

Mozobil, a hematopoietic stem cell mobilizer, is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The following codes may be appropriate to describe these conditions:

| ICD-9-CM Diagnosis Code       | Description  | CMS-1500 Location                                   |
|-------------------------------|--|---|
| <b>Multiple Myeloma</b>       |  |   |
| 203.0X                        | Multiple myeloma   | Boxes 21 and 24E DIAGNOSIS and DIAGNOSIS POINTER    |
| <b>Non-Hodgkin's Lymphoma</b> |  |   |
| 200.0X                        | Reticulosarcoma  | Boxes 21 and 24E<br>DIAGNOSIS and DIAGNOSIS POINTER |
| 200.1X                        | Lymphosarcoma  |   |
| 200.2X                        | Burkitt's tumor or lymphoma  |   |
| 200.3X                        | Marginal zone lymphoma   |   |
| 200.4X                        | Mantle cell lymphoma   |   |
| 200.5X                        | Primary central nervous system lymphoma                                      |   |
| 200.6X                        | Anaplastic large cell lymphoma   |   |
| 200.7X                        | Large cell lymphoma  |   |
| 200.8X                        | Lymphosarcoma, other named variants  |   |
| 202.0X                        | Nodular lymphoma   |   |
| 202.1X                        | Mycosis fungoides  |   |
| 202.2X                        | Sezary's disease   |   |
| 202.3X                        | Malignant histiocytosis  |   |
| 202.4X                        | Leukemic reticuloendotheliosis   |   |
| 202.5X                        | Letterer-Siwe disease  |   |
| 202.6X                        | Malignant mast cell tumors   |   |
| 202.7X                        | Peripheral T-cell lymphoma   |   |
| 202.8X                        | Other lymphomas  |   |
| 202.9X                        | Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue |   |

The fifth digit, X, identifies further specificity regarding disease location.

## MOZOBIL DRUG CODE

Healthcare Common Procedure Coding System (HCPCS) Level 2 codes are used to report drugs. Effective January 1, 2010, the HCPCS code assigned to Mozobil is J2562. Report this HCPCS code in Box 24D PROCEDURES, SERVICES, OR SUPPLIES CPT/HCPCS of the CMS-1500 claim form.

| HCPCS | Description                 | CMS-1500 Location                            |
|-------|-----------------------------|--|
| J2562 | Injection, plerixafor, 1 mg | Box 24D<br>PROCEDURES, SERVICES, OR SUPPLIES |

Mozobil is supplied in a single-use vial filled to deliver 1.2 mL of a 20 mg/mL solution containing 24 mg of plerixafor, and has the 10-digit NDC number 58468-0140-1. For claims processing purposes, if billing with the NDC number, make the NDC 11 digits by adding a leading zero to the last segment of the NDC: 58468-0140-01.

When billing with J2562, specify the total number of units administered to the patient on the claim form. Each single use vial of MOZOBIL contains 24 mg or 24 units of J2562.

**24 units of MOZOBIL must be billed to reflect a full single dose vial**

**Example: 24mg product X 1 billing unit per mg = 24 billing units**

NOTE: Though Medicare typically will reimburse unused drug from single use vials when it is medically reasonable to discard product, the practices of other payers regarding this practice may vary. Please contact your payer for specific coverage details.

## MOZOBIL ADMINISTRATION CODE

Current Procedural Terminology (CPT) codes are used to report the administration of Mozobil. Based on the FDA-approved method of administration for Mozobil, the physician should list an appropriate CPT code for the administration of Mozobil in Box 24D PROCEDURES, SERVICES, OR SUPPLIES of the CMS-1500 claim form. Prescribing information indicates Mozobil is administered via a subcutaneous injection. Per 2010 CPT code guidelines, a subcutaneous injection is reported with 1 unit (Box 24G) of the following CPT code:

| CPT   | Description   | CMS-1500 Location                            |
|-------|---|--|
| 96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | Box 24G<br>PROCEDURES, SERVICES, OR SUPPLIES |

**MOZOBILDirect** – is a reimbursement resource for healthcare providers and patients. It provides support to help patients and providers better understand reimbursement for Mozobil. You can call the help line toll-free at 1-877-4MOZOBIL (1-877-466-9624) and select option 3 for personalized support with:

- Benefit Verifications
- Coding assistance
- Claims assistance
- Claim denial assistance
- Prior authorization assistance
- Co-insurance foundation assistance
- Patient Assistance Program

1500

HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE 08/05

Physician Office
Sample CMS-1500 (08-05)
Mozobil™ (plerixafor injection)

CARRIER

PATIENT AND INSURED INFORMATION

PHYSICIAN OR SUPPLIER INFORMATION

This document is provided for your guidance only. Please call MOZOBILDirect at 1-877-4MOZOBIL (1-877-466-9624) and select option 3 to verify coding and claim information for specific payers.

Box 21: Diagnosis Code
Enter the appropriate ICD-9-CM diagnosis code.
Example: 203.01 Multiple Myeloma in remission.
Note: Enter the appropriate diagnosis as reflected in the patient's medical record.

Box 24G: Days or Units
Enter the appropriate number of units.
Example: Each single use vial of MOZOBIL contains 24 mg or 24 units of J2562. 24 units of MOZOBIL must be billed to reflect a full single dose vial.
Note: 24mg product X 1 billing unit per mg = 24 billing units.

Box 24D: Procedures, Services, or Supplies
Enter appropriate HCPCS code.
Example: J2562, Injection, plerixafor, 1mg.
Enter appropriate CPT codes for drug administration services.
Example: 96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular.

Main form grid containing fields for patient information, insurance details, diagnosis codes (21), procedures/services (24), charges (24G), and provider information.

Please see accompanying full Prescribing Information.

## IMPORTANT SAFETY INFORMATION

- Mozobil may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. Therefore, Mozobil is not intended for hematopoietic stem cell (HSC) mobilization and harvest in patients with leukemia
- Mozobil in conjunction with G-CSF increases circulating leukocytes and HSC populations. White blood cell counts should be monitored during treatment. Clinical judgment should be exercised when administering Mozobil to patients with peripheral white blood cell counts above 50,000/mcL
- Thrombocytopenia has been observed in patients receiving Mozobil. Platelet counts should be monitored in patients who receive Mozobil and then undergo apheresis
- In patients treated with Mozobil in combination with G-CSF for HSC mobilization, tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. The effect of potential re-infusion of tumor cells has not been well studied
- The effect of Mozobil on spleen size was not specifically evaluated in clinical studies. Individuals receiving Mozobil in combination with G-CSF who report left upper abdominal pain and/or scapular or shoulder pain should be evaluated for splenic integrity
- Mozobil may cause fetal harm when administered to a pregnant woman. Plerixafor was teratogenic in animals. There are no adequate and well-controlled studies in pregnant women using Mozobil. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Mozobil
- The most common adverse reactions ( $\geq 10\%$ ) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), fatigue (27%), injection site reaction (34%), headache (22%), arthralgia (13%), dizziness (11%), and vomiting (10%). The majority of these adverse reactions were Grade 1 and 2

### DO YOU HAVE ADDITIONAL REIMBURSEMENT QUESTIONS?

Please call MOZOBILDirect for assistance toll-free at 1-877-4MOZOBIL (1-877-466-9624) and select option 3, Monday through Friday, 9:00 AM to 7:00 PM EST.

Please see accompanying full Prescribing Information.